Clinical trial
Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute…
NCT00442936 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00442936 |
|---|---|
| Title | Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011) |
| Official title | A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Study to Compare the Response to a Single Treatment With Oral MK0974 With Placebo and Comparator in Subjects With Moderate to Severe Acute Migraine With or Without Aura |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Migraine |
| Intervention type | Drug |
| Interventions | Telcagepant potassium 150 mg, Telcagepant potassium 300 mg, Zolmitriptan 5 mg, Placebo to telcagepant 150 mg, Placebo to tecagepant 300 mg, Placebo to zolmitriptan 5 mg, Rescue medication |
| Enrollment | 1,380 |
| Start date | Feb 15, 2007 |
| Primary completion | Oct 2, 2007 |
| Completion | Oct 2, 2007 |
| First posted | Mar 5, 2007 |
| Last update posted | Oct 17, 2018 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: